Figure 6

Effects of hWJMSC-MVs administration on expression of CX3CL1 in injured kidney in vivo and HUVECs in vitro . (A) IHC localization of CX3CL1 in the kidney 48 h after IRI. CX3CL1 was mainly expressed on endothelial cells (arrow points to positively stained endothelial cells; the original magnification is 200×, Scale bar = 50 um). (B, C) CX3CL1 expression in kidney tissues was measured by Western blot analysis, and MVs dramatically decreased the CX3CL1 expression. Data are expressed as mean ± SD of three experiments (n = 3, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle; **P <0.05, sham versus MVs). (D) ICC of CX3CL1 in HUVECs 48H after hypoxia injury (the original magnification is 200×, Scale bar = 50 um). (E, F) CX3CL1 expression in HUVECs was measured by Western blot analysis, and MVs dramatically decreased the CX3CL1 expression both in 24 h and 48 h after hypoxia. Data are expressed as mean ± SD of the three experiments (n = 3, *P <0.05, sham versus vehicle; #P <0.05, MVs versus vehicle). hWJMSC-MVs, human Wharton-Jelly mesenchymal stem cell derived microvesicles; IHC, immunohistochemistry; MVs, microvesicles.